歐康維視生物-B(01477.HK)出售EyePoint(EYPT.US)逾291萬股 套現5,666萬美元
歐康維視生物-B(01477.HK)公布,於紐約時間去年5月30日至12月6日期間在公開市場透過一系列交易,及自今年1月11日起至今日(17日)期間,以大宗交易方式出售合共291.05萬股EyePoint(EYPT.US)股份,佔其已發行股份總數約5.96%,總代價約為5,665.8萬美元(約4.43億港元)。
其中,於紐約時間去年5月30日至12月6日期間,集團於公開市場出售合共100萬股EyePoint股份,帶來已實現收益約1.14億元人民幣(下同)。而自今年1月11日起至今日,集團以大宗交易方式出售191.05萬股EyePoint股份,該部分至去年12月底止年度的未實現收益約2.26億元,自今年1月1日起至今已實現虧損約4,870萬元。
完成後,集團直接持有EyePoint約10.02萬股,佔其已發行股份總數約0.21%。公司預期該等出售事項產生的所得款項淨額約為4.03億元,並擬用作集團一般公司用途的營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.